Christine Siu
Chief Operating Officer at BRIDGEBIO PHARMA, INC.
Net worth: - $ as of 31/03/2024
Profile
Ms. Christine E. Siu is a Chief Operating Officer at BridgeBio Pharma, Inc. She is on the Board of Directors at Vividion Therapeutics, Inc. and Monte Rosa Therapeutics, Inc. Ms. Siu was previously employed as a Chief Financial & Accounting Officer by Eidos Therapeutics, Inc., a Chief Business Officer by The Bluefield Project to Cure Frontotemporal Dementia, a Senior Director-Operations & Business Development by Global Blood Therapeutics, Inc., a Principal by Third Rock Ventures LLC, a Vice President by Thomas, McNerney & Partners LLC, an Analyst by Bear, Stearns & Co., Inc., and a Portfolio Manager by Warburg Pincus LLC. She also served on the board at NeuroTherapeutics Pharma, Inc. She received her undergraduate degree from the University of Michigan and an MBA from Harvard Business School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Christine Siu active positions
Companies | Position | Start |
---|---|---|
MONTE ROSA THERAPEUTICS, INC. | Director/Board Member | 01/12/2020 |
BRIDGEBIO PHARMA, INC. | Chief Operating Officer | 01/01/2020 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Director/Board Member | 04/05/2021 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Director/Board Member | 10/06/2021 |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Director/Board Member | - |
Former positions of Christine Siu
Companies | Position | End |
---|---|---|
EIDOS THERAPEUTICS, INC. | Director of Finance/CFO | 31/12/2019 |
The Bluefield Project to Cure Frontotemporal Dementia | Corporate Officer/Principal | 01/01/2017 |
GLOBAL BLOOD THERAPEUTICS, INC. | Chief Operating Officer | 01/01/2014 |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | Private Equity Analyst | 31/12/2010 |
░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Christine Siu
University of Michigan | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BRIDGEBIO PHARMA, INC. | Health Technology |
MONTE ROSA THERAPEUTICS, INC. | Health Technology |
Private companies | 11 |
---|---|
Bear, Stearns & Co., Inc.
Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information. | Finance |
Warburg Pincus LLC
Warburg Pincus LLC Investment ManagersFinance Warburg Pincus LLC (Warburg Pincus) is a private equity subsidiary of Warburg Pincus & Company US LLC founded in 1966. The firm is headquartered in New York. | Finance |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | Finance |
NeuroTherapeutics Pharma, Inc.
NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL. | Health Technology |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Health Technology |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
The Bluefield Project to Cure Frontotemporal Dementia |
- Stock Market
- Insiders
- Christine Siu